News >

FDA Grants Zanubrutinib Priority Review for Relapsed/Refractory Mantle Cell Lymphoma

Gina Columbus @ginacolumbusonc
Published: Wednesday, Aug 21, 2019

The FDA has granted a priority review designation to a new drug application (NDA) for zanubrutinib (BGB-3111) for the treatment of patients with mantle cell lymphoma (MCL) who have received ≥1 prior therapy.1

The application is based on data from an international phase I/II trial (NCT02343120) in patients with B-cell lymphomas, a group of patients with relapsed/refractory MCL in China in a phase II trial (NCT03206970), pooled safety data from 5 clinical trials, and nonclinical data, stated BeiGene, the developer of the investigational BTK inhibitor.

Under the Prescription Drug User Fee Act, the FDA must make a decision on the NDA by February 27, 2020.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication